Tempus xF Liquid Biopsy Assay Demonstrates Extensive Analytical and Clinical Validity in npj Precision Oncology Study
Tempus, a leader in artificial intelligence and precision medicine, today announced results from validation studies demonstrating the reliable analytical performance of the Tempus|xF liquid biopsy. When validated against methods such as ddPCR, the Roche AVENIO kit, and the Tempus|xT solid tumor assay, xF demonstrated high sensitivity and specificity for calling SNVs, indels, CNVs, and [...]